US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Aimmune Therapeutics

34.49

0.0000

Volume:- -

Turnover:- -

Market Cap:2.27B

PE:-7.68

High:34.49

Open:34.49

Low:34.49

Close:34.49

52wk High:37.00

52wk Low:10.09

Shares:65.77M

Float Shares:43.20M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.4923

EPS(LYR):-3.9723

ROE:-149.17%

ROA:-53.24%

PB:12.61

PE(LYR):-8.68

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Aimmune Therapeutics

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

http://www.aimmune.com

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/AIMT/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"AIMT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AIMT\",,,,,undefined,":{"symbol":"AIMT","market":"US","secType":"STK","nameCN":"Aimmune Therapeutics","latestPrice":34.49,"timestamp":1602532800000,"preClose":34.49,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":43200031,"shares":65766796,"eps":-4.492338,"marketStatus":"Halted","change":0,"latestTime":"10-12 16:00:00 EDT","open":34.49,"high":34.49,"low":34.49,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.492338,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1438833600000,"exchange":"NASDAQ","adjPreClose":34.49,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AIMT\",,,,,undefined,":{"symbol":"AIMT","floatShares":43200031,"roa":"-53.24%","roe":"-149.17%","lyrEps":-3.972265,"shares":65766796,"dividePrice":0,"high":34.49,"amplitude":0,"preClose":34.49,"low":34.49,"week52Low":10.09,"pbRate":"12.61","week52High":37,"institutionHeld":0,"latestPrice":34.49,"eps":-4.492338,"divideRate":0,"volume":0,"delay":0,"ttmEps":-4.492338,"open":34.49,"prevYearClose":33.47},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AIMT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2020-10-14","symbol":"AIMT","reason":null,"defaultRemindTime":1602682200000,"announcedDate":"2020-10-06","type":"delisting","dateTimestamp":1602648000000},{"market":"US","date":"2020-07-30","symbol":"AIMT","fiscalQuarterEnding":"2020/06","expectedEps":-1.06,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1596081600000,"reportTimeType":"post","actualEps":-1.06},{"market":"US","date":"2020-05-11","symbol":"AIMT","fiscalQuarterEnding":"2020/03","expectedEps":-1.15,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1589169600000,"reportTimeType":"post","actualEps":-1.18},{"market":"US","date":"2020-02-27","symbol":"AIMT","fiscalQuarterEnding":"2019/12","expectedEps":-1.05,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1582779600000,"reportTimeType":"post","actualEps":-1.06},{"date":"2019-11-06","symbol":"AIMT","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2019/09","expectedEps":-1.01,"defaultRemindTime":1573074000000,"name":null,"time":"Post Market","dateTimestamp":1573016400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AIMT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AIMT\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AIMT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AIMT","date":"2020-10-12","current":-7.677517,"percent":0.758829,"low":-156.52467,"twenty":-39.061253,"median":-18.04372,"eighty":-7.721404,"high":-2.734035,"avg":-24.599876,"sd":25.490591,"marketCap":2274873473},"quantilePoints":[],"updateTime":1771756977282},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.aimmune.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0113},{"period":"1month","weight":0.0059},{"period":"3month","weight":0.0461},{"period":"6month","weight":0.0684},{"period":"1year","weight":0.1295},{"period":"ytd","weight":0.011}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.","exchange":"NASDAQ","name":"Aimmune Therapeutics","nameEN":"Aimmune Therapeutics"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"AIMT\",market:\"US\",,,undefined,":null}}